Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repotrectinib + Trametinib in KRAS-mutant solid tumors
NCT05071183Phase 2Terminated
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of repotrectinib in solid tumor, sponsored by Turning Point Therapeutics, Inc.. Started Sep 2021; status: terminated.
02
Drugs
repotrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05071183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071183.